Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy recommendation. Analyst Price Forecast Suggests 113.85% Upside As of March 5, 2025, ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Bringing the woolly mammoth back to life is no easy task. But for Ben Lamm, CEO of Colossal Biosciences, the stress of the ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The exploration of mitochondrial mechanisms in cancer stem cells (CSCs) presents a promising frontier in cancer research, with significant implications for ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...

The second act of a popular reprogramming factor could maximize the potential of iPSCs in research and regenerative medicine.

This paper presents the important finding that BNIP3/NIX, a mitophagy receptor, and its binding to ATG18 are required for mitophagy during muscle cell reorganization in Drosophila. Although the ...

The applied physicist explains how the structure of 52,000-year-old genes hint at the biology of an extinct animal ...

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study. The discovery could lead ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...